I am a transplant hepatologist at the University of North Carolina in Chapel Hill. I have a special interest in alcohol-related liver disease, and I am the Director of UNC's Integrated Healthcare for Alcohol Use and Liver Disease (IHEAL) Clinic. I am active in AASLD through my work as a co-founder of Liver Fellow Network and currently as Chair of AASLD's Practice Metrics Committee.

Richard Jaenisch, MPH is a patient advocate for liver transplantation, and HCV. As a survivor and caregiver, he extends his lived experience to his work at both Open Biopharma Research and Training Institute and Prompting Integration and Consulting LLC. Richard has always been involved in the digital patient experience from online moderation of forums, content creation and being a patient stakeholder, this is continued this by expanding his area of advocacy to include work in data and artificial intelligence.

Assistant Professor of Medicine at Duke University

Karen is an author, educator, writer, blogger, and patient advocate. Personal experience includes acute liver failure, advanced liver disease, Hepatitis C, liver cancer, liver transplant, sarcopenia, pre and post transplant nutrition, rural health care, and stigma. Her passion is patient empowerment. Serves AASLD, GLI A3, FDA, NVHR, Trio, WHA, WTGF

Dr. Howard Lee (he/him/his) is a transplant hepatologist and assistant professor at Baylor College of Medicine, Houston, Texas. He completed his internal medicine residency, gastroenterology, and transplant hepatology fellowship at Duke. Dr. Lee's academic interests include viral hepatitis, liver transplant, technologies and applications, and diversity, equity, and inclusion, with a special focus on the LGBTQ+ population. Dr.

Dr. Barnard Giustini has an appointment as an assistant professor in the University of Washington's Department of Medicine and currently serves as the Liver Clinic Director for the VA Puget Sound Health Care System. She is the hepatology lead for the VA Extension for Community Healthcare Outcomes for her region which is a virtual continuing education program with a diverse national attendance including physicians, advanced practice providers, pharmacists, social workers, and nutritionists.

Dr. Romil Saxena is Professor in the Department of Pathology and Laboratory Medicine, Director of the Liver Pathology Service, and Director of the Gastrointestinal and Liver Pathology Fellowship at Emory University School of Medicine, Atlanta, USA. Dr. Saxena completed fellowships in Liver Pathology at King's College Hospital, London, Liver Pathology and Gene Therapy at Mount Sinai School of Medicine, NYC and in Gastrointestinal Pathology at Yale University Medical Center.

Daniela Allende MD MBA is a Professor of Pathology. She has served in many leadership roles, including Vice Chair of Research, Director of Clinical Affairs for the Pathology Division, GI/HPB subspecialty director and currently as Board of Governor Professional Advancement Council, Chair of the Governance Committee, and Vice Chair of the Conflict of Interest and Innovation Management Committee at Cleveland Clinic. She is the President of the Latin American Pathology Foundation and Vice President of Hans Popper Hepatopathology Society.

Dr. Thomas D. Schiano is Professor of Medicine in the Division of Liver Diseases at the Icahn School of Medicine at Mount Sinai, and is the Medical Director of the Adult Liver Transplant program, Medical Director of Intestinal Transplantation, and Medical Director of VCA Transplantation at the Recanati/Miller Transplant Institute at the Mount Sinai Medical Center.

Dr. Kakar is a Professor of Pathology and Chief of GI-Hepatobiliary Pathology at University of California San Francisco (UCSF). He completed medical school in India and pathology residency at University of Illinois at Chicago followed by fellowships in GI/Hepatobiliary Pathology and Molecular Pathology at Mayo Clinic in Rochester, MN. He joined UCSF in 2002, where he has served as the Chief of the GI/Hepatobiliary Pathology and GI/Hepatobiliary Pathology fellowship director since 2015.